Cyclerion Therapeutics (NASDAQ: CYCN) is a clinical-stage biopharmaceutical company focused on developing treatments for neuropsychiatric disorders. Revenue, where generated, has come from license agreements, purchase agreements, and option agreements, as disclosed in the FY2025 consolidated statements of operations (10-K filed 2026-03-31). The company holds no commercial products as of December 31, 2025 and reports an accumulated deficit, operating without product revenue. In September 2025, Cyclerion entered an exclusive worldwide patent license with MIT covering technology for neuropsychiatric conditions including depression, under which MIT is eligible to receive up to $4.4 million in development, regulatory, and sales milestones, plus tiered royalties in the low single digits on future net sales. The company also holds an other investment of $5.4 million in Tisento Therapeutics Holdings Inc. as of December 31, 2025. CEO Regina Graul serves as President and Principal Executive Officer, with Rhonda Chicko as CFO.

Revenue model

Revenue derived from license agreements, purchase agreements, and option agreements, as reported in FY2025 and FY2024 consolidated statements of operations. No product sales revenue disclosed. Future revenue model, if products reach market, would include royalties to MIT in the low single-digit percentage range on net sales.

Products and services

Pipeline focused on neuropsychiatric disorders, including depression, using technology exclusively licensed from MIT under the MIT License Agreement signed September 19, 2025. No approved or commercialized products disclosed as of December 31, 2025. Active pharmaceutical ingredients sourced from third-party suppliers.

Customers and end markets

No commercial customers disclosed. Target end market is neuropsychiatric disorder treatment, specifically depression in humans, per the MIT License Agreement (signed September 19, 2025). Pre-revenue stage as of December 31, 2025.

Value-chain role

Early-stage drug developer. Relies on third-party contract manufacturers and suppliers for active pharmaceutical ingredients. Uses third-party cloud infrastructure and other service providers for operations.

Geographic exposure

MIT license grants exclusive worldwide rights. Company listed on The Nasdaq Capital Market. No specific geographic revenue breakdown disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations Peers: Achieve Life Sciences Inc Acurx Pharmaceuticals Inc Protara Therapeutics Inc Orgenesis Inc. CASI Pharmaceuticals, Inc (DE) Eledon Pharmaceuticals Inc Gain Therapeutics Inc Molecular Templates, Inc. Tracon Pharmaceuticals, Inc.